Imagion Biosystems is pleased to provide an update on its progress and plans for manufacturing of its proprietary nanoparticle formulation in advance of the first in human study currently planned for mid-2020.
Read the update.
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
May 25, 2023
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session